nitric oxide (NO) and cytokines (tumor necrosis factor-␣ and interleukin 1 ␤ ), and treatment with NaPA or lovastatin decreased the synthesis of NO. Our data indicate that X-ALD lymphoblasts are significantly affected by the accumulation of VLC fatty acids, which induces changes in the cell membrane properties/functions that may, in turn, play a role in the development/progression of the pathogenesis of X-ALD disease.
cally, the disease can develop as a severe form (cerebral form) which progresses very rapidly, with fatal consequences, and a mild form (adrenomyeloneuropathy) that affects axonal tracts of the spinal cord, inducing progressive physical disabilities towards adulthood [7] . Both disease phenotypes can be triggered by the same genetic mutation, indicating the participation of a modifier gene and/or environmental factors [8] . The cerebral form begins with the accumulation of VLC fatty acids in peripheral and neural tissue (metabolic stage), then, due to an unknown event, the disease progresses to an inflammatory process characterized by activation of microglia, synthesis of nitric oxide (NO), cytokines, chemokines and further infiltration of macrophages and T cells, finally inducing oligodendrocyte cell death (inflammatory stage) [7, [9] [10] [11] . Interestingly, the findings that the animal models of X-ALD (ALDP knockout mouse) do not express a clear disease phenotype during developmentalthough they accumulate VLC fatty acids in the central nervous system [12] [13] [14] -or do not show evidence of oxidative stress in nervous tissue during development as in X-ALD patient samples [15, 16] suggest that induction of an oxidative imbalance in X-ALD patients may play a role in the development/progression of the severe form of the disease.
NADPH oxidases are a group of plasma-membraneassociated enzymes, of which the most studied is the leukocyte's NADPH oxidase, found in professional phagocytes and B lymphocytes [17] . The oxidase catalyzes the production of superoxide ( O 2 -) which is utilized for the production of reactive oxidants that phagocytes use to kill microorganisms [18] . The enzyme consists of one of each of 5 subunits, 3 of which are cytoplasmic (p40 PHOX , p47 PHOX , p67
PHOX
) and 2 of which are membrane anchored (p22 PHOX , gp91 PHOX ) [17] . NADPH oxidases have become the focus of attention due to the discovery that they may play a role in the development/progression of inflammation in disorders affecting the CNS [19] .
Studies using X-ALD patient-derived cells or mutant cells (C6) exposed to VLC fatty acids indicate that these cells have altered membrane signaling and that they become prone to overrespond when stimulated. For example, peripheral blood mononuclear cells from X-ALD patients, when stimulated with bacterial lipopolysaccharide, produce increased levels of cytokines typical of a Th1 cell response (interleukin (IL)-12; tumor necrosis factor (TNF)-␣ ) as compared to cells from control patients [20, 21] ; skin fibroblasts derived from patients with peroxisomal metabolic disorders (including X-ALD) have an increased basal as well as IL-1 ␤ -stimulated arachidonic acid metabolism [22] , and C6 cells enriched in the VLC fatty acid hexacosanoic acid (C 26: 0 ) and stimulated with oxidative stressors (lipopolysaccharide, oxidized lowdensity lipoprotein) produce higher levels of NO and O 2 -products as compared to those by untreated cells [23] . These reports support the hypothesis that accumulation of VLC fatty acids alters the plasma membrane properties [24, 25] , and hence cell-signaling functions in those cell membranes [26] .
Free radicals play a significant role in the development and progression of the pathobiology of most neurodegenerative diseases, including X-ALD [15] . Indeed, studies performed with plasma, red blood cells, skin fibroblasts and nervous tissues from X-ALD patients reported significant evidence of an oxidative imbalance in those samples [15, 16] . However, the source of such oxidative imbalance remains unknown, as it is not known whether it is a contributing cause for and/or an effect of the development/progression of X-ALD disease. Unfortunately, animal models of X-ALD express later on in life a mild form of the human disease, adrenomyeloneuropathy [27] , and signs of oxidative stress in the spinal cord during adulthood [28] . Consequently, study of the contribution of oxidative imbalance to the development/progression of the cerebral form of X-ALD disease is limited, at present, to patient-derived tissues only. Therefore, to gain an insight into what might be potential sources contributing to the observed oxidative stress in X-ALD patients, we studied the activity and expression of NADPH oxidase in control-and X-ALD patient-derived lymphoblasts. Here, we report that X-ALD lymphoblasts are prone to synthesize NADPH oxidase-dependent free radicals, NO and cytokines as compared to control cells, with some of these products being susceptible to pharmacological treatment. These events are probably a consequence of the accumulation of VLC fatty acids in the cell membrane, which results in alterations of its properties and functions.
Materials and Methods
Materials RPMI-1640 (containing L -glutamine) was from Cellgro (Mediatech, Herndon, Va., USA). Fetal bovine serum was from Atlanta Biologicals (Norcross, Ga., USA); trypsin and Hanks' balanced salt solution were from Gibco (Grand Island, N.Y., USA). Antibodies against gp91 PHOX , p47
PHOX and p67 PHOX were from Santa Cruz Biotechnology (Santa Cruz, Calif., USA); anti-ALDP was from Chemicon Inc. (Temecula, Calif., USA); anti-PMP70 was custom made against C-terminal residues 644-659 of the human protein. Diphenylene iodonium (DPI), bovine serum albu-min, imidazole, Triton X-100, Tween-20 and ␤ -mercaptoethanol were purchased from Sigma-Aldrich Chemical Co. (St. Louis, Mo., USA). All chemicals and reagents used were of analytical grade or of the highest purity commercially available.
Methods

Cell Culture
Human B-lymphoblasts derived from normal (control, GM03798), X-ALD (hemizygote, GM04673 and GM13496) and carrier (heterozygote, GM04674) patients were obtained from the NIGMS Human Genetic Mutant Cell Repository at the Coriell Institute for Medical Research (ccr.coriell.org/). The lymphoblasts were cultured in RPMI-1640 containing 10% fetal bovine serum and antibiotic/antimycotic, at a cell density of less than 2 ! 10 6 cells/ml. Most of the studies were performed with the X-ALD lymphoblast cell line GM04673 derived from a patient with a positive family history of X-ALD (11-year-old male whose cultured fibroblasts presented elevated VLC (C 26: 0 ) fatty acid levels. Clinically, he had adrenal insufficiency, progressive white matter disease and progressively deteriorating intellectual and motor function). Lymphoblasts GM13496 were from a 9-year-old boy that presented elevated C 26: 0 fatty acid levels. Heterozygote lymphoblast (GM04674) was from a 30-year-old female with a family history of X-ALD (ccr.coriell.org/). Normal (control) cells (GM03798) were from an apparently healthy 10-year-old male.
Measurement of VLC Fatty Acids Fatty acid methyl esters were prepared as described previously [29] . Briefly, lymphoblasts were suspended in Hanks' balanced salt solution, and disrupted by sonication (10 s at 8-9 W output power in a VirSonic 100; VirTis, Gardiner, N.Y., USA). An aliquot of this solution was transferred to a glass tube and an internal standard (heptacosanoic acid, 5 g) was added; the lipids were extracted by Folch partition. Fatty acids were trans-esterified with acetyl chloride in the presence of methanol and benzene (4: 1) for 2 h at 100 ° C. The solution was cooled down to room temperature followed by addition of 5 ml 6% potassium carbonate solution at ice-cooled temperature. Isolation and purification of fatty acid methyl esters were carried out as described elsewhere [29] . Purified fatty acid methyl esters were suspended in chloroform and analyzed by gas chromatography (GC-15A; Shimadzu Corporation, Durham, N.C., USA).
Preparation of Total and Carbonate Membranes
Cells were harvested with sucrose buffer (0.25 M sucrose, 1 m M EDTA, 3 m M imidazole buffer, pH 7.4), and subjected to sonication (10 s at 8-9 W output power). The homogenate was centrifuged at 2,500 rpm for 5 min to remove unbroken cells. To isolate total membranes from control and ALD homogenates, equal protein amounts were centrifuged at 50,000 rpm for 30 min at 4 ° C using a TLA-100.2 rotor (Beckman-Coulter, Fullerton, Calif., USA), and the pellets were washed once with cold water and dissolved in an equal volume of electrophoresis sample loading buffer (100 m M Tris-HCl (pH 6.8), 250 m M sucrose, 4% (w/v) sodium dodecylsulfate, 0.01% (w/v) bromophenol blue and 5% (v/v) ␤ -mercaptoethanol). To isolate carbonate membranes (membrane sheets containing integral membrane proteins), equal protein amounts from control and X-ALD cell homogenates were diluted with an ice-cold solution of 0.1 M sodium carbonate (pH 11.5) containing 30 m M iodoacetamide. After 30 min of incubation at 4 ° C, carbonate membranes were sedimented by centrifugation at 35,000 rpm for 1 h in a 70Ti rotor (Beckman-Coulter). The sedimented membranes were washed twice with cold water, lyophilized and stored at -70 ° C until use.
Western Blot Analysis Equal amounts of protein were heated in sample-loading buffer and subjected to SDS-PAGE (4-20% Tris-HCl Criterion gradient Gel; Bio-Rad Laboratories, Hercules, Calif., USA) [6] . Proteins were then transferred to nitrocellulose membrane (Bio-Rad), blocked with 5% nonfat milk (Bio-Rad) in Tween-20-Tris-buffered saline (20 m M Tris-HCl (pH 7.6), 137 m M NaCl, 0.05% Tween-20) for 1 h, and incubated overnight with specific antibodies at 4 ° C in 5% nonfat milk-Tween-20-Tris-buffered saline. Blots were washed and incubated 90 min with an alkaline-phosphatase-conjugated secondary antibody (Pierce, Rockford, Ill., USA). Signals were detected with Lumi-Phos WB chemiluminescence substrate (Pierce) and exposure to CL-Xposure films (Pierce).
Quantitative Real-Time PCR Total RNA was purified from lymphoblasts using TRIzol (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's protocol. cDNA was synthesized from RNA by using the iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's instructions. For quantitative real-time PCR (qRT-PCR), a master mixture was prepared using the SYBRGreen PCR Master Mix (Applied Biosystems, Foster City, Calif., USA) and dispensed into microplate wells together with template and primers. Primers used were (SuperArray, Frederick, Md., USA): gp91 PHOX (CYBB, cat. No. PPH10407A); p67 PHOX (NCF2, cat. No. PPH07033A), and p47 PHOX (NCF1, cat. No. PPH07085E). Thermal cycling conditions were as follows: activation of DNA polymerase at 95 ° C for 10 min, 40 cycles of amplification at 95 ° C for 15 s, and 60 ° C for 60 s. The expression of target gene was normalized to the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH, cat. No. PPH00150E). All samples were run in triplicate.
Measurement of Reactive Oxygen Species
Intracellular reactive oxygen species (ROS) were determined using the membrane-permeable fluorescent dye 6-carboxy 2 ,7 -dichlorodihydrofluorescein (H 2 DCFDA; Molecular Probes, Eugene, Oreg., USA). Cells (1 ! 10 6 cells/ml) were preincubated in the presence or absence of the NADPH oxidase inhibitor DPI (10 M ) for 30 min and then exposed to 10 M H 2 DCFDA in PBS for 30 min. Changes in fluorescence were determined by reading emission at 530 nm after excitation at 485 nm, using a SoftMax Pro spectrofluorometer (Molecular Devices, Sunnyvale, Calif., USA).
Assay for NO Synthesis Synthesis of NO was determined in cell culture supernatants by measuring nitrite, a stable product of the reaction of NO with molecular oxygen. Briefly, 400 l of culture supernatant was reacted with 200 l of Griess reagent [30] for 15 min at room temperature, and the color developed was measured at 570 nm using a SpectraMax microplate reader (Molecular Devices).
Cytokine Analysis Lymphoblasts were cultured in serum-free RPMI-1640 for 72 h. Cell-free supernatants were collected and TNF-␣ and IL-1 ␤ levels were determined using ELISA kits (R&D Systems, Minneapolis, Minn., USA).
Drug Treatments
Lymphoblasts were incubated in complete medium containing either 1 M lovastatin or 1 m M sodium phenylacetate (NaPA), during 7 days, with daily replacement of media-containing drugs. At the end of the treatment, VLC fatty acid levels (C 26:0 ) were determined in harvested cells and nitrite was determined in the cell culture supernatants.
Determination of Protein Content
Protein determination was performed using the method of Bradford [31] (Bio-Rad reagent).
Statistics
Data are expressed as the mean 8 standard deviation (SD) for n number of experiments. Statistical differences were analyzed using Student's t test. p ! 0.05 was considered a statistically significant difference.
Results
Molecular and Biochemical Alterations in X-ALD Lymphoblasts
First, we characterized control (GM03798), X-ALD (ALD1: GM04673; ALD2: GM13496) and heterozygote (GM04674) lymphoblasts in terms of the expression of the peroxisomal transporter (ALDP/ABCD1), the gene product defective in X-ALD, and the peroxisomal membrane protein of 70 kDa (PMP70/ABCD3). Western blots using antibodies against ALDP and PMP70 were performed on carbonate membranes (membrane preparations containing integral membrane proteins) obtained from control, X-ALD and heterozygote cultured lymphoblasts. The analysis indicated that ALDP was not detectable in ALD1 and barely detectable in ALD2 when compared with the levels expressed in control and heterozy- gote ( fig. 1 a) . On the other hand, screening of PMP70 did not show an appreciable difference between the signals obtained from the same cell samples analyzed. Further studies were performed with ALD1 lymphoblasts from a patient with a positive family history of X-ALD disease (ccr.coriell.org/). Gas chromatography analysis of the levels of C 26: 0 fatty acids determined in whole cell homogenates of control and X-ALD (ALD1) lymphoblasts indicated a significant accumulation of C 26: 0 in X-ALD cells (8.37 8 0.3 times; p ! 0.0001), a biochemical hallmark of X-ALD disease ( fig. 1 b) . This observation was supported by a significant increase in the C 26: 0 /C 22: 0 ratios in X-ALD lymphoblasts ( fig. 1 c) . Next, we tested two drugs (NaPA and lovastatin), which in previous studies from our laboratory have demonstrated to be of benefit in lowering the levels of VLC fatty acids in plasma of X-ALD patients and in X-ALD fibroblasts in culture [32] [33] [34] . Treatment of X-ALD lymphoblasts with NaPA, lovastatin or a combination of both drastically reduced the elevated levels of C 26: 0 after 2 days ( fig. 1 d) . These results indicate that VLC fatty acids metabolism in X-ALD lymphoblasts is susceptible to NaPA and lovastatin treatment as reported previously for X-ALD fibroblasts [33] .
NADPH-Oxidase-Dependent Synthesis of ROS in Nonstimulated X-ALD Lymphoblasts
Based on published reports which indicate evidence of oxidative stress in X-ALD fibroblasts [16] and induction of free radicals in cell culture exposed to VLC fatty acids [23] , we investigated whether X-ALD lymphoblasts could be prone to higher ROS synthesis under basal (nonstimulated) conditions, using the permeable fluorescent probe H 2 DCFDA. Determination of ROS levels in control and X-ALD lymphoblasts in culture indicated that X-ALD lymphoblasts synthesized significantly higher levels of free radicals as compared to control (1.45 8 0.08 times, p ! 0.0001) ( fig. 2 ) . To establish that the free radicals synthesis was NADPH oxidase-dependent, we further treated the cells with DPI, an inhibitor of the enzyme [35] . Pretreatment of X-ALD lymphoblasts with DPI significantly reduced the free-radicals levels ( fig. 2 ) , suggesting that the oxidase contributes, at least in part, to the observed synthesis of ROS in nonstimulated X-ALD lymphoblasts.
To investigate the possible mechanism of the observed increase in the synthesis of ROS by NADPH oxidase, we assessed the protein levels and gene expression of gp91 PHOX , the catalytic subunit of NADPH oxidase which is localized in the plasma membrane [17] . The study of the catalytic subunit gp91
PHOX protein levels by Western blot in cell homogenate ( fig. 3 a) and in total membranes ( fig. 3 b) demonstrated a significant increase in the subunit in samples from X-ALD lymphoblasts but not in those from control. To further evaluate whether the signal obtained from the membrane ( fig. 3 b) represents the gp91 PHOX subunit which is anchored to or is associated with the cell membrane, we obtained carbonate membranes (i.e. membranes containing integral membrane proteins [36] ) and screened them with antibodies against gp91 PHOX and PMP70. In addition, we included a sample from ALD2 and heterozygote lymphoblasts to rule out individual cell line variations. The analysis using carbonate membranes demonstrated that gp91
PHOX subunit is present at higher levels in the samples from the X-ALD hemizygotes than the samples from control and heterozygote lymphoblasts, whereas not much difference was observed in the levels of the integral membrane protein PMP70 when examined in those samples ( fig. 3 c) . Surprisingly, the mRNA level of gp91 PHOX in X-ALD1 lymphoblasts was not significantly different from the levels found in control lymphoblasts ( fig. 3 c) . To evaluate whether this finding is specific for gp91
PHOX or a phenomenon that affects all the subunits, Western blot analysis was performed with specific antibodies against the two cytoplasmic subunits p47 PHOX , p67 PHOX in homogenate, total membranes, and cytosolic fractions. The analysis in total homogenate ( fig. 4 a) as well as in the total membranes and cytosolic fractions ( fig. 4 b) indicated that there were no significant changes in the protein levels of those subunits of NADPH oxidase in X-ALD lymphoblasts as compared to control. The mRNA analysis was consistent with the previous results, showing no appreciable differences in p47 PHOX and p67 PHOX mRNA levels ( fig. 4 c,  d ). These data suggest that changes in the cell membrane properties of X-ALD lymphoblasts may be responsible for the higher protein levels of the gp91 PHOX subunit observed in the X-ALD samples.
NO and Cytokines (TNF-␣ and IL-1 ␤ ) Synthesis in Nonstimulated X-ALD Lymphoblasts
As reported earlier, peripheral blood mononuclear cells from X-linked ALD patients synthesize excessive levels of the proinflammatory cytokine TNF-␣ when stimulated with bacterial lipopolysaccharide [20, 21] . Therefore, we investigated whether lymphoblasts are able to synthesize cytokines under nonstimulated conditions. We first determined the synthesis of NO released into the culture media in 24 h under serum-free conditions. The analysis showed that X-ALD lymphoblast production of NO is 2.1 times that of controls ( fig. 5 a) . Further determi- PHOX of NADPH oxidase was determined in total homogenate ( a ), and total membrane fractions ( b ) using specific antibodies. ␤ -Actin and Na + /K + -ATPase (plasma membrane protein) were used as indicators of protein loading for homogenate ( a ) and membrane fractions ( b ), respectively. The levels of gp91 PHOX subunit anchored in the cell membrane were analyzed by Western blot on the carbonate membrane fractions obtained from control (CTL: GM03798), cerebral X-ALD patients (ALD1: GM04673; ALD2: GM13496), and heterozygote (HZ: GM 04674) ( c ). PMP70 was screened as indicators of protein loading for the carbonate membrane preparations (integral membrane proteins). Western blots are representative of 3 different experiments. The gp91 PHOX gene expression was determined by qRT-PCR analysis, and normalized to the expression of GAPDH ( d ), as indicated in the Methods section. The data represent the average 8 SD of n = 3 experiments done in triplicate. nation of the cytokines TNF-␣ and IL-1 ␤ indicated increased synthesis (2.1 and 2.3 times, respectively) of both cytokines in X-ALD lymphoblasts as compared to controls ( fig. 5 b, c) . In addition, we tested whether the increased production of NO is susceptible to NaPA and lovastatin pharmacologic regulation. The synthesis of NO was markedly reduced by NaPA, and moderately by lovastatin; however, combination of NaPA plus lovastatin did not reduce NO synthesis further than NaPA alone after 7 days of treatment ( fig. 5 d) .
Discussion
The progression of X-ALD disease encompasses two clear stages: a metabolic stage characterized by accumulation of VLC fatty acids in organs and body fluids and an inflammatory stage characterized by an immunoinflammatory response in the nervous system [7, 9] . What triggers the transition from the metabolic to the inflammatory stage is still unknown, and the involvement of a modifier gene has been suggested [8] . Differences found between X-ALD patients and the murine model of the disease [27] and the lack of clear expression of the disease in the animals, although they accumulate VLC fatty acids in the nervous system [12] [13] [14] , suggest that oxidative stress may participate in the development/progression of the disease in X-ALD patients [16] .
Here, we report the activity of NADPH oxidase and the expression of its catalytic subunit gp91
PHOX in control and X-ALD lymphoblast cell lines in culture, under nonstimulated conditions. Our data indicate that X-ALD lymphoblasts accumulate VLC fatty acids and synthesize higher levels of free radicals. In addition, those cells present higher levels of the membrane-anchored NADPH oxidase subunit gp91
PHOX , but not of the cytoplasmic subunits p47 PHOX or p67 PHOX , without showing a significant increase in its mRNA levels. These data suggest that the accumulation of VLC fatty acids in X-ALD lymphoblasts may cause the increased levels of the catalytic subunit of NADPH oxidase gp91
PHOX observed in total cell homog- [21, [23] [24] [25] [26] . Interestingly, the signal from the gp91 PHOX subunit observed by immunoanalysis of cell homogenates or total membrane samples is mainly the contribution of the protein being anchored in the membrane, as indicated by screening of membrane preparations that basically contain integral membrane proteins, and the use of the membrane protein PMP70 as a marker [36] . Taking into consideration that gp91
PHOX is an integral membrane protein [17] , our data indicate that changes in the X-ALD cell membrane lipid environment may be interfering with its turnover, as we did not observe changes in its mRNA levels. Those results suggest that most of this protein is incorporated in the cell membrane, and, based on the analysis of two different X-ALD lymphoblast cell lines, the data indicate that this observation appears to be a characteristic of the oxidase's subunit in X-ALD lymphoblasts, as it was present at low levels in the control and the heterozygote lymphoblasts analyzed. Unfortunately, there are no available lymphoblasts derived from the mild form of the disease (i.e. adrenomyeloneuropathy); therefore, we cannot test how they will behave. In addition, Western blot analysis also indicates that a fraction of the other two cytoplasmic subunits of the NADPH oxidase (p47 PHOX and p67
PHOX
) was associated with the membranes at similar levels in control and X-ALD lymphoblasts, suggesting that the higher levels of synthesis of free radicals observed in X-ALD lymphoblasts may be a consequence of the higher levels of the catalytic subunit gp91
PHOX . The results also indicate that X-ALD lymphoblasts produce higher levels of NO and TNF-␣ and IL-1 ␤ cytokines, suggesting additional alterations of other membrane proteins, and support previous studies reporting that cells derived from X-ALD patients display an increased proinflammatory response [20] [21] [22] . Taken together, the data suggest that free radicals produced by NADPH oxidase may play an important role as modulators of the development/progression of neuroinflammation in X-ALD disease.
Fatty acids have been described as potential NADPH oxidase activators in fibroblasts [37] , neutrophils [38] , and endothelial cells [39] ; therefore, activation of the enzyme in X-ALD lymphoblasts due to changes in the membrane fatty acids composition is also possible. This assertion gets additional support from a study indicating that C6 cells enriched with VLC fatty acids synthesize higher amounts of NO and O 2 -products compared to native C6 cells when stimulated [23] . Although the mechanism of O 2 -synthesis was not investigated, these data support the hypothesis that accumulation of VLC fatty acids may be altering membrane microdomains (lipid rafts) important for cell signaling [25, 26, 40] .
Our observation that NaPA or lovastatin treatments can decrease the accumulation of VLC fatty acids levels and downregulate the synthesis of NO in X-ALD lymphoblasts suggest that these drugs may have pharmacological potential for the treatment of both the metabolic and the inflammatory disease of X-ALD, and support previously published data that indicated that lovastatin normalized the plasma levels of VLC fatty acids in X-ALD patients and that lovastatin or NaPA treatments normalized the VLC fatty acid levels of X-ALD fibroblasts in culture [32] [33] [34] .
